Artiva grants director Moore 16,250 stock options

Artiva Biotherapeutics granted director Alison Moore 16,250 stock options at a $10.42 exercise price, vesting by the 2027 annual stockholder meeting.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that director Alison Moore received a grant of options to purchase 16,250 shares of common stock on September 10, 2026. The options have an exercise price of $10.42 per share and will vest in full on the earlier of September 10, 2027, or the company’s 2027 annual stockholder meeting, and expire on September 9, 2036. No Rule 10b5-1 trading plan is reported for this award.

Insider Trade Summary

Grant/Award: 16,250 shares

Grant/Award 1 txn

Insider MOORE ALISON

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	16,250	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 16,250 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

Key Figures

Options granted: 16,250 options Exercise price: $10.42 per share Vesting date: September 10, 2027 +3 more

6 metrics

Options granted 16,250 options Grant to director Alison Moore on September 10, 2026

Exercise price $10.42 per share Exercise price for the 16,250 stock options

Vesting date September 10, 2027 Options vest in full on this date or earlier at the 2027 annual stockholder meeting

Alternative vesting trigger 2027 annual stockholder meeting Options vest in full on the earlier of this meeting or September 10, 2027

Expiration date September 9, 2036 Date on which the granted options expire

Options held after transaction 16,250 options Total options from this award held by Alison Moore after the grant

Key Terms

Director Stock Option (Right to Buy), vest in full, annual stockholder meeting

3 terms

Director Stock Option (Right to Buy) financial

"security titled Director Stock Option (Right to Buy) relating to common stock"

vest in full financial

"The shares subject to the option will vest in full on the earlier"

annual stockholder meeting financial

"the date of the Issuer's 2027 annual stockholder meeting"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTV report for director Alison Moore?

ARTV reported that director Alison Moore received a grant of 16,250 stock options on September 10, 2026. These options give her the right to buy Artiva Biotherapeutics common stock at a fixed exercise price, subject to vesting and expiration terms.

What is the exercise price of the new stock options granted by ARTV?

The options granted to Alison Moore have an exercise price of $10.42 per share. This is the price at which she may purchase Artiva Biotherapeutics common stock once the options vest and before they expire, according to the reported award terms.

When do Alison Moore’s ARTV stock options vest?

The options will vest in full on the earlier of September 10, 2027, or the date of Artiva Biotherapeutics’ 2027 annual stockholder meeting. She must wait until vesting occurs before exercising the options, based on the disclosed vesting schedule.

When do the ARTV stock options granted to Alison Moore expire?

The stock options granted to Alison Moore are scheduled to expire on September 9, 2036. After this expiration date, any unexercised options would no longer be available to purchase Artiva Biotherapeutics common stock under this award.

How many ARTV options does Alison Moore hold after this grant?

Following this reported grant, Alison Moore holds 16,250 stock options relating to Artiva Biotherapeutics common stock from this award. All of these options are subject to the vesting and expiration terms described in the filing.

Were Alison Moore’s ARTV option grants made under a Rule 10b5-1 plan?

No. The filing indicates that no Rule 10b5-1 trading plan is associated with this reported option grant to Alison Moore. The award is reported as a grant of options without reference to any pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:03 PM Accepted by SEC EDGAR 09/14/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOORE ALISON

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$10.42	09/10/2026		A		16,250		(1)	09/09/2036	Common Stock	16,250	$0	16,250	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of September 10, 2027, or the date of the Issuer's 2027 annual stockholder meeting.

	/s/ Jennifer Bush, Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)